Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Auxotrophic vaccines for tuberculosis

I Guleria1, R Teitelbaum, R A McAdam

  • 1Howard Hughes Medical Institute, Bronx, New York 10461, USA.

Nature Medicine
|March 1, 1996
PubMed
Summary

New tuberculosis (TB) vaccine strains, auxotrophic bacille Calmette-Guerin (BCG), show promise for HIV-positive individuals. These modified BCG strains were found to be safe and effective in mouse models, offering potential protection against TB.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Edge-AI enabled secure IoT framework for real-time patient monitoring and anomaly detection in smart healthcare systems.

Scientific reports·2026
Same author

Advanced image preprocessing and context-aware spatial decomposition for enhanced breast cancer segmentation.

MethodsX·2025
Same author

Enhanced figure of merit in two-dimensional ZrNiSn nanosheets for thermoelectric applications.

Nanotechnology·2024
Same author

First-principles study on novel Fe-based quaternary Heusler alloys, with robust half-metallic, thermoelectric and optical properties.

RSC advances·2023
Same author

Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study.

Journal of family medicine and primary care·2023
Same author

Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: A systematic review and meta-analysis.

HLA·2017

Area of Science:

  • Immunology
  • Infectious Diseases
  • Vaccinology

Background:

  • Tuberculosis (TB) remains a leading infectious cause of death globally, particularly impacting HIV-infected individuals.
  • The bacille Calmette-Guerin (BCG) vaccine is widely used but its safety in HIV-positive adults is a concern.
  • Developing safer TB vaccines for immunocompromised populations is critical.

Purpose of the Study:

  • To evaluate the safety and efficacy of novel auxotrophic BCG strains in immunocompromised mouse models.
  • To determine if auxotrophic BCG strains offer protection against Mycobacterium tuberculosis challenge.
  • To assess the potential of auxotrophic BCG as a safer TB vaccine alternative.

Main Methods:

  • Auxotrophic BCG strains were created using insertional mutagenesis.

Related Experiment Videos

  • Safety was assessed in severe combined immunodeficiency (SCID) mice.
  • Efficacy was evaluated by challenging immunized BALB/c mice with virulent Mycobacterium tuberculosis.

    • Main Results:

    • Auxotrophic BCG strains were cleared from SCID mice within 16-32 weeks, with prolonged survival (≥230 days) compared to conventional BCG (≤8 weeks).
    • Auxotrophic BCG strains provided protection comparable to conventional BCG against both intravenous and intratracheal M. tuberculosis challenge in BALB/c mice.
    • No adverse effects were observed in SCID mice receiving auxotrophic BCG.

    Conclusions:

    • Auxotrophic BCG strains demonstrate enhanced safety profiles in immunocompromised models.
    • These auxotrophic BCG strains offer significant protection against tuberculosis infection.
    • Auxotrophic BCG strains represent a promising, potentially safer vaccine candidate for populations at risk for HIV.